• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- Study: Readmission rate for COVID-19 is 11%

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/news-perspective/2022/05/study-readmission-rate-covid-19-11


Study: Readmission rate for COVID-19 is 11%


Filed Under:
COVID-19
Stephanie Soucheray | News Reporter | CIDRAP News

May 16, 2022

Eleven percent of Canadian patients who were discharged after hospitalization for COVID-19 were readmitted to the hospital or died within 30 days of discharge, according to a study today in CMAJ (Canadian Medical Association Journal).

The retrospective cohort study was based on the medical records of all adults hospitalized in Alberta and Ontario for SARS-CoV-2 from Jan 1, 2020, to Sep 30, 2021. A total of 46,412 (5.5%) adults had a positive COVID-19 test 14 days prior or during their hospital admission. Of these, 8,496 died in hospital and 34,846 were discharged alive.

Of those discharged, 30,336 had a typical hospital stay — 30 days or less. A total of 4,510 had a stay greater than 30 days, and 14% required intensive care unit admission. The median length of hospital stay was 8 days.

"One in 9 discharged patients died or were readmitted within 30 days after discharge," the authors said, including 10.5% of those with a typical hospital stay, and 12.8% of those with a stay of more than 30 days.

Patients who were readmitted or died were more likely to be older, male, discharged to a long-term care facility, and have a medical history of multiple hospitalizations. Non-specific pneumonia was the most often cited reason for readmission (37.6%), followed by non-specified pneumonia or interstitial pulmonary disease (6.0%), heart failure (4.1%), pulmonary embolism (3.1%) and confusion (3.0%).

Of all patients admitted with COVID-19 in both provinces, 91% in Alberta and 95% in Ontario were unvaccinated.

"Identifying risk factors for early readmission or death is important for both the in-hospital clinical team and the primary care physician who reassumes care after discharge, as well as for transition coordinators deciding which patients may benefit from additional resources at discharge to optimize outcomes," said University of Alberta researcher Finlay McAlister, PhD, a coauthor
of the study, in a press release.

Readmission rates similar to other illnesses


The study authors said the readmission rates for COVID-19 were similar to other respiratory tract illnesses which require hospitalization, suggesting the system for discharge in Alberta and Ontario hospitals did not need to be adjusted.

Length of hospital stay and in-hospital death rates were higher for COVID-19 patients, however.

One significant complication not included in the study was long COVID, the authors said, which typically does not require readmission to a hospital but may be a costly outcome for hospitalized patients.

"Future research should determine other system effects for COVID-19 survivors, particularly with respect to postacute COVID-19 symptomatology," the authors concluded.
 
Back
Top Bottom